"BRCA2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
| Descriptor ID |
D024682
|
| MeSH Number(s) |
D12.776.313.249 D12.776.624.776.101 D12.776.660.105
|
| Concept/Terms |
BRCA2 Protein- BRCA2 Protein
- FANCD1 Protein
- Fanconi Anemia Complementation Group D1 Protein
- Fanconi Anemia Group D1 Protein
- BRCA2 Gene Product
- Breast Cancer 2 Gene Product
- Fanconi Anemia Group D1 Complementing Protein
- Breast Cancer 2 Protein
|
Below are MeSH descriptors whose meaning is more general than "BRCA2 Protein".
Below are MeSH descriptors whose meaning is more specific than "BRCA2 Protein".
This graph shows the total number of publications written about "BRCA2 Protein" by people in this website by year, and whether "BRCA2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2010 | 5 | 0 | 5 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "BRCA2 Protein" by people in Profiles.
-
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 06 01; 26(11):2546-2555.
-
Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. PLoS One. 2019; 14(12):e0226714.
-
Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers. Ann Surg Oncol. 2020 Feb; 27(2):367-372.
-
Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? J Surg Oncol. 2019 May; 119(6):777-783.
-
Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Res. 2017 Jul 19; 19(1):83.
-
Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial. Genet Med. 2017 04; 19(4):448-456.
-
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. Eur J Cancer. 2013 Sep; 49(14):2979-85.
-
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013 Feb 01; 31(4):433-9.
-
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010 May 10; 28(14):2404-10.
-
Effect of genetic counseling and testing for BRCA1 and BRCA2 mutations in African American women: a randomized trial. Public Health Genomics. 2010; 13(7-8):440-8.